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Abstract
Introduction: Molecular dissection of the signaling pathways that underlie complex biological responses in the
mammary epithelium is limited by the difficulty of propagating large numbers of mouse mammary epithelial cells,
and by the inability of ribonucleic acid interference-based knockdown approaches to fully ablate gene function.
Here we describe a method for the generation of conditionally immortalized mammary epithelial cells with defined
genetic defects, and we show how such cells can be used to investigate complex signal transduction processes
using the transforming growth factor beta (TGFb)/Smad pathway as an example.
Methods: We intercrossed the previously described H-2Kb-tsA58 transgenic mouse (Immortomouse), which
expresses a temperature-sensitive mutant of the simian virus-40 large T-antigen (tsTAg), with mice of differing
Smad genotypes. Conditionally immortalized mammary epithelial cell cultures were derived from the virgin
mammary glands of offspring of these crosses and were used to assess the Smad dependency of different
biological responses to TGFb.
Results: IMECs could be propagated indefinitely at permissive temperatures and had a stable epithelial phenotype,
resembling primary mammary epithelial cells with respect to several criteria, including responsiveness to TGFb.
Using this panel of cells, we demonstrated that Smad3, but not Smad2, is necessary for TGFb-induced apoptotic,
growth inhibitory and epithelial-to-mesenchymal transition responses, whereas either Smad2 or Smad3 can support
TGFb-induced invasion as long as a threshold level of total Smad is exceeded.
Conclusions: The present work demonstrates the practicality and utility of generating conditionally immortalized
mammary epithelial cell lines from genetically modified Immortomice for detailed investigation of complex
signaling pathways in the mammary epithelium.
Introduction
Transforming growth factors beta (TGFbs) are widely
expressed cytokines that play complex roles in both nor-
mal physiology as well as pathological states [1,2]. In the
mammary gland, TGFbs and their cognate receptors are
expressed throughout the development of the gland,
where they maintain ductal morphogenesis and architec-
ture, regulate stem cell populations, influence epithelial
proliferation and differentiation in response to hormonal
cues, and induce apoptosis in the involuting gland
(reviewed in [3-5]). These activities are important for
maintenance of homeostasis in the normal mammary
gland. Indeed, reduction of TGFb signaling in the mam-
mary gland has been associated with inappropriate differ-
entiation and accelerated tumorigenesis in numerous
models, and reduced expression of TGFb receptors in
breast cancer patients correlates with disease progression
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any medium, provided the original work is properly cited.(reviewed in [5-7]). Paradoxically however, high levels of
TGFb are often detected in advanced human breast can-
cer, and many preclinical studies have demonstrated that
TGFb can promote metastasis in late-stage disease,
through direct effects on the tumor cell such as enhanced
motility, invasion, and survival, as well as through effects
on the tumor stroma, such as regulation of extracellular
matrix composition, stimulation of angiogenesis and sup-
pression of immunosurveillance (reviewed in [5-7]).
These findings demonstrate important and complex roles
for TGFb in the normal and diseased mammary gland,
and reveal a strong need to better understand the
mechanisms by which TGFb regulates these varied
responses.
Canonical signaling by TGFbs is activated by binding
of the ligands to cell surface receptors, which then phos-
phorylate the receptor-activated Smad (R-Smad) pro-
teins, Smad2 and Smad3 [8]. The R-Smads generally
partner with a common mediator Smad (Smad4) and
translocate to the nucleus, where they regulate gene
transcription. Smad2 and Smad3 share a very high
degree of homology, with 92% identity at the amino acid
level. Genetic knockout studies have revealed a critical
role for Smad2 in embryogenesis, whereas Smad3 null
m i c ea r ev i a b l ea n ds u r v i v eu n t i la d u l t h o o d[ 9 ] .T h e s e
distinct phenotypes could represent differing expression
patterns rather than intrinsically different activities,
however, as insertion of Smad3 into the Smad2 locus is
sufficient to rescue lethality in Smad2 null mice [10].
More definitive evidence for distinct biological activ-
ities of the two Smads comes from a number of studies.
Transcriptome analysis in mouse embryo fibroblasts
treated with TGFb revealed that Smad3 appeared to be
the dominant transcriptional regulator downstream of
the TGFb receptor, and that Smad2 functioned primar-
ily in a transmodulatory fashion [11]. Targeted genetic
knockout studies have also indicated distinct roles for
the two Smads in epithelial homeostasis and response to
injury in the liver [12] and the skin [13]. Importantly, it
is apparent that different cell types can show different
Smad requirements for a given biological response. For
example, the cytostatic response to TGFb is lost in
Smad2 null mouse embryo fibroblasts [14], but is
enhanced in the HaCAT human keratinocyte cell line
following siRNA-mediated knockdown of Smad2 [15];
and the inhibitory effect of TGFb on T-cell proliferation
requires Smad3, while the inhibitory effect on B-cell
proliferation does not [16]. Smad utilization thus
appears to be contextual and must be studied specifi-
cally in the cell type of interest.
Given the complex dual role of TGFb in breast cancer
tumorigenesis, and the desire to generate TGFb pathway
antagonists that might selectively block pro-progression
and not tumor suppressor activities of TGFb, we wished
to determine whether the two TGFb R-Smads contri-
bute differentially to these two classes of activity in the
normal and transformed mammary epithelium. Since
gene knockdown by RNA interference approaches can
never fully ablate the target protein, complete genetic
inactivation is necessary to definitively show a require-
ment for the protein of interest in a given biological
response, and this can only be achieved in the mouse.
Unlike the situation with human breast epithelium,
however, only a small number of mammary cells can be
obtained from one mouse, and typically these cells can
only be propagated for a few days in vitro before under-
going apoptosis [17], posing a challenge for detailed
molecular and biochemical analyses.
In 1991 Jat and colleagues generated a mouse (the
Immortomouse) that transgenically expressed a tem-
perature-sensitive form of the SV40 Large T antigen
(tsTAg) from a broadly-expressing MHC antigen pro-
moter [18]. Conditionally immortalized cells from this
model can be expanded and propagated under permis-
sive conditions (33°C with IFNg) and reacquire many
properties of primary cultures under semipermissive or
nonpermissive conditions (37°C or 39°C without IFNg).
This approach has been exploited successfully in the
study of many rare cell types, including epithelial cells
from the cochlea [19] and proximal convoluted tubule
of the kidney [20]. In the present study, we have crossed
the Immortomouse with mice of differing Smad geno-
types to generate a panel of conditionally immortalized
mammary epithelial cells (IMECs) that allow us to
cleanly dissect the role of the two Smads in different
biological responses to TGFb. This approach has gener-
ated interesting biological insights, and should also be
broadly applicable to the study of other signal transduc-
tion pathways in the mammary epithelium.
Materials and methods
Generation of IMEC cultures of different Smad genotypes
A schematic for the overall strategy for IMEC generation
i ss h o w ni nF i g u r e1 .T h eH-2Kb-tsA58 transgenic
Immortomouse was obtained from Charles River Labora-
tories (Wilmington, MA, USA). Smad3DelEx8 mice in
which the Smad3 gene is constitutively inactivated by
i n s e r t i o no fan e o m y c i nc D N Ai ne x o n8w e r eo b t a i n e d
from Chuxia Deng (National Institute of Diabetes, Diges-
tive and Kidney Diseases, Bethesda, MD, USA) [16], and
Smad2LoxPEx2 mice in which exon2 is floxed for condi-
tional deletion were generated as described previously
[12]. All animal studies were performed under approved
protocols in compliance with the National Cancer Insti-
tute’s Animal Care and Use Committee guidelines for the
ethical treatment of animals.
Mice were intercrossed to generate offspring that had
the Immortomouse transgene together with various
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IMECs were prepared from 12-week-old virgin mice.
Briefly, the number four and number nine (inguinal)
mammary glands were aseptically removed and minced
with scalpel blades in Ham’s F-12 medium supplemen-
ted with 10% fetal bovine serum (FBS), 5 μg/ml insulin,
10 ng/ml epidermal growth factor, 100 units/ml penicil-
lin, 100 μg/ml streptomycin, and 1 mg/ml collagenase
(blend L; Sigma-Aldrich, St. Louis, MO, USA). Following
overnight incubation in this medium at 37°C, the mix-
ture was centrifuged and the fat was removed. The
remaining pellet was washed four times in collagenase-
free medium and then resuspended in fresh medium
and incubated at 37°C. After 4 hours, the medium con-
taining the epithelial cells was transferred to a new dish;
the fibroblasts, which attach to the plate much more
quickly, were left behind. The following day, the med-
ium containing dead cells and other nonattached debris
was removed and fresh medium was added. After 3
days, numerous epithelial colonies could be observed.
Some fibroblast contamination was also present; these
cells were selectively removed by light trypsinization
(0.25% trypsin in 1 mM ethylenediamine tetraacetic
acid; Invitrogen, Carlsbad, CA, USA) for 5 minutes at
room temperature. The epithelial culture was trypsi-
nized, pipetted up and down to generate a single cell
suspension, centrifuged and resuspended in fresh media
containing 30 units/ml IFNg to stimulate the MHC
promoter driving tsTAg expression, and incubated at
33°C, the permissive temperature for the tsTAg. After
passage through a partial crisis at 7 days, during which
~50% of the cells die, the culture could be stably main-
tained with minimal further cell death.
For expansion and continuous propagation, cells were
grown at 33°C (5% carbon dioxide) in Ham’sF - 1 2
media supplemented with 10% FBS, 10 ng/ml epidermal
growth factor, 5 μg/ml insulin, 1 μg/ml hydrocortisone,
5 ng/ml cholera toxin, 50 μg/ml gentamycin (complete
media) and 30 units/ml IFNg. For experiments, cells
were plated and incubated at 37°C (5% carbon dioxide)
in the absence of IFNg for 2 to 4 days prior to the assay
to allow for decay of the tsTAg protein.
For ex vivo excision of floxed Smad2, cells were
transduced with Adeno-Cre virus (Ad5-CMV-Cre),
which was purchased from the University of Iowa
Gene Transfer Vector Core (Iowa City, IA, USA). For
Smad add-back experiments, adeno-LacZ, Adeno-
Smad2 and Adeno-Smad3 were obtained from the late
Dr Anita Roberts (National Cancer Institute, Bethesda,
MD, USA).
Immunofluorescence
To immunostain for vimentin and cytokeratins, IMECs
were plated in complete media at a density of 5,000
cells/well in 24-well plates. After the cell culture reached
70 to 80% confluence, the medium was removed and
cells were washed three times with PBS. Cells were then
fixed with methanol for 10 minutes at -20°C and
blocked with 0.5% casein for 1 hour with agitation at
room temperature. Then cells were dual stained with
mouse anti-vimentin (1:200; Sigma) and guinea pig anti-
keratin (1:100; Sigma) at 4°C overnight. The following
day, cells were washed with PBS and incubated with
rabbit anti-guinea pig tetramethyl rhodamine isothiocya-
nate (Sigma) and horse anti-mouse fluorescein isothio-
cyanate (Vector Laboratories, Burlingame, CA, USA)
secondary antibodies for 1 hour at room temperature.
Cell nuclei were stained with 4’,6-diamidino-2-pheny-
lindole. Swiss 3T3 cells were used as a positive control
for fibroblasts. To immunostain for E-cadherin and
F-actin, cells were plated into an eight-well chamber
slide (Nunc Labtek, Thermo Fisher Scientific, Waltham,
MA, USA). Cells were fixed with 4% paraformaldehyde
for 15 minutes and then permeabilized by 0.1% Tri-
tonX-100/PBS (Sigma) for 10 minutes at room tempera-
ture. Cells were stained with rat anti-uvomorulin/E-
cadherin antibody (clone DECMA-1, 1:100; Sigma) or
phalloidin (Alexa Fluor 594, 1:100; Invitrogen) at 4°C
overnight. The next day, cells were washed with PBS
and cells stained for E-cadherin were incubated with
goat anti-rat IgG (Alexa fluor 555, 1:500; Invitrogen)
secondary antibody for 1 hour at room temperature.
Figure 1 Using the Immortomouse in combination with
genetically modified mice to generate conditionally
immortalized cell cultures. General scheme for breeding strategy,
generation and propagation of conditionally immortalized cells.
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dole. Images were acquired a Nikon Eclipse E800 fluor-
escent microscope (Nikon Instruments Inc., Linthicum
Heights, MD, USA) with a Roper Photometrics Cool
SNAP fx camera (Roper Scientific GmbH, Ottobrun,
Germany) and IPLab 4.0.8 software (BD Biosciences,
Franklin Lakes, NJ, USA).
Quantitative RT-PCR and western blots
For analysis of SV40 T-antigen expression, IMECs were
seeded in 100 mm
2 culture plates in either permissive
conditions (33°C with IFNg) or nonpermissive conditions
(37°C without IFNg). After 4 days in culture, RNA or pro-
tein was isolated and tsTAg expression was analyzed by
RT-PCR or western blotting, respectively. For analysis of
epithelial-to-mesenchymal transition (EMT) markers,
cells were grown under the nonpermissive conditions in
complete medium for 24 hours, then switched to med-
ium with reduced serum (0.5% FBS) for a further 18 to
24 hours and, finally, were treated with 2 ng/ml TGFb
for 48 hours prior to isolation of RNA and protein. For
all gene targets, total RNA was isolated using the RNeasy
kit (Qiagen Inc, Valencia CA, USA) according to the
manufacturer’s instructions. cDNA synthesis was carried
out using M-MLV reverse transcriptase (Invitrogen). The
primer sequences for tsTAg are as follows: forward, 5’-
GGTGTAAATAGCAAACAAGCAAG-3’; and reverse,
5’-GAATGGGAGCAGTGGTGGAATG-3’. All quantita-
tive RT-PCR data were normalized to cyclophilin A
(PP1A) as an internal control for each sample.
For western blot analysis of phospho-Smads, cells
were treated as specified for analysis of EMT markers
above, except that protein lysates were harvested after
30 minutes of TGFb treatment. For western blots of
tsTAg, lysates were harvested at various timepoints.
Total protein (40 μg) was electrophoresed on 4 to 20%
Tris-glycine gels and transferred to polyvinylidene fluor-
ide membranes. Membranes were blocked with 5%
bovine serum albumin (for anti-Smad2) or 5% nonfat
dry milk (for all other antibodies) in Tris-buffered saline
with Tween for 45 minutes at room temperature, and
were then incubated with primary antibody solutions
o v e r n i g h ta t4 ° C .T h ep r i m a r ya n t i b o d i e su s e dw e r ea s
follows: anti-Smad2 (Zymed Laboratories Inc., San
Franscisco, CA, USA), anti-phospho-Smad2 (Cell Signal-
ing Technology Inc., Danvers, MA, USA), anti-Smad3
( A b c a m ,C a m b r i d g e ,M A ,U S A ) ,a n t i - p h o s p h o - S m a d 3
(Epitomics Inc., Burlingame, CA, USA), anti-b-actin
(Sigma) and anti-tsTAg (Oncogene Research Products,
La Jolla, CA, USA). All were used at a 1:1,000 dilution.
Secondary antibodies (anti-rabbit, 1:2,000; anti-mouse,
1:8,000) conjugated to horseradish peroxidase were
applied for 45 minutes at room temperature, followed
by incubation with chemiluminescent reagent (Super
Signal; Thermo Scientific Pierce Protein Research Pro-
ducts, Rockford, IL, USA) and exposure to autoradiogra-
phy film (Eastman Kodak Co., Rochester, NY, USA).
Gelatin zymography
Following 48 hours of treatment with 2 ng/ml TGFb in
medium containing 0.5% FBS, cell culture supernatants
were collected and centrifuged at 400 × g for 5 minutes.
Cell-free culture supernatants were collected, mixed
with Brij-35 (final concentration 0.02%), and stored at
-20°C until further use. For zymography, samples were
mixed with 6× sample buffer and electrophoresis was
performed using precast zymography gels (10% polya-
crylamide, 0.1% gelatin; Invitrogen). Proteins were rena-
tured with Renaturing Buffer (Invitrogen) twice for 15
minutes, and zymograms were developed in Developing
Buffer (Invitrogen) for 72 hours at room temperature.
Gelatinase activity was visualized by staining gels with
Coomassie Brilliant Blue G250 (0.25% Coomassie Brilli-
ant Blue G250, methanol 30%, acetic acid 10%) and
destained with acetic acid/methanol/dH2O (1:3:6). Gels
were imaged using a flatbed scanner.
Flow cytometry
IMECs were grown to ~80% confluence in complete
media at 37°C. After harvesting by trypsinization, cells
were fixed and permeabilized in a Cytofix/Cytoperm
solution (Becton Dickinson, Franklin Lakes, NJ, USA),
washed with permeabilization/wash solution (Becton
Dickinson), and incubated with primary antibody (anti-
cytokeratin 8; Developmental Studies Hybridoma Bank,
Iowa City, IA, USA; and anti-cytokeratin 14; Covance,
Princeton, NJ, USA) for 16 hours at 4°C. Following
washes and incubation with secondary antibodies for 45
minutes at room temperature, cells were re-suspended
in staining buffer and analyzed by flow cytometry using
a FACSCaliber(tm) instrument (BD Biosciences, San
Jose, CA, USA) with FlowJo software (Treestar, Ashland,
OR, USA).
Growth inhibition and apoptosis assays
To determine effects of TGFb on growth inhibition,
IMECs were plated in 24-well tissue culture plates at a
density of 15,000 cells/0.5 ml/well in complete media
and were shifted from the permissive temperature to
37°C. On day 3, culture medium was changed to Ham’s
F-12 medium containing 1% FBS and insulin (5 μg/ml)
to suppress apoptosis. Recombinant human TGFb1
(R&D Systems, Minneapolis, MN, USA) was added to
cells at various concentrations and incubated for 24
hours. Tritiated thymidine (0.5 μCi) was then added to
wells for an additional 4 hours. Cells were then washed,
trypsinized and transferred to a filter mat using a Cell
Harvester. [
3H]Thymidine incorporation was assessed
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Elmer, Waltham, MA, USA). To assess apoptosis,
IMECS were plated in a 96-well plate at a density of
4,000 cells/0.2 ml/well in complete medium. Two days
later, culture medium was changed to Ham’sF - 1 2c o n -
taining 0.2% FBS, and cells were treated with different
concentrations of TGFb for 24 hours. Apoptosis was
then measured using the Cell Death Detection ELISA
kit (Roche Applied Science, Indianapolis, IN, USA),
which measures DNA-histone complexes that are gener-
ated during apoptotic cell death.
Cell migration and invasion
Cell migration and invasion assays were carried out
using the Transwell® System (8 μm; BD Biosciences, San
Jose, CA, USA). Transwell® inserts are uncoated for
migration assays, and are coated with Matrigel(tm) for
invasion assays. Briefly, 25,000 IMECs (migration) or
50,000 IMECs (invasion) were plated in complete med-
ium in the top chamber; the bottom chamber was also
filled with complete medium. After allowing the cells to
attach for 3 to 4 hours, TGFb was added to both cham-
bers of each well. Plates were incubated for 2 days, and
cells that remained in the top chamber were removed.
The membranes were then fixed, stained with hematox-
ylin and mounted on microscope slides, and the number
of cells in 10 high-powered fields (40× objective) per
membrane was visually quantified.
Lactogenic differentiation assay
Cells were grown to near-confluence at the nonpermis-
sive temperature and then switched to fresh growth
medium containing charcoal-stripped serum and a lacto-
genic hormone cocktail (5 μg/ml insulin, 1 μMd e x a -
methasone and 1 μg/ml ovine prolactin). The medium
was changed daily. Cells were harvested after 72 hours
of hormone exposure and were assessed for expression
of the milk protein casein by western blot analysis of
cell lysates. In some experiments, cells were grown in
collagen-coated dishes and exposed to lactogenic hor-
mones for up to 12 days. Similar results were obtained,
however, under both sets of conditions.
Transplantation into the mammary fat pad
All animals were maintained according to the National
Cancer Institute’s Animal Care and Use Committee
guidelines, under approved animal study protocols.
The inguinal fat pads of 3-week-old mice were cleared
of endogenous epithelium as described previously [21],
and several different inocula of IMECs, ranging from
2.5 × 10
4 to 2 × 10
6, were implanted into the cleared
fat pads. Each recipient received IMECs in one fat pad
and a medium control in the contralateral fat pad.
After 10 weeks, the transplanted tissue was harvested
for whole-mount analysis. The transplanted glands
were removed and spread on a glass slide. After fixa-
tion for 2 to 4 hours in Carnoy’ss o l u t i o n ,g l a n d sw e r e
hydrated and stained with Carmine alum, dehydrated
and mounted as described previously [22]. Whole
mounts were directly imaged with a CCD camera
mounted on a Zeiss ICM405 microscope (Carl Zeiss
Inc, Thornwood, NY, USA).
Results
Generation and characterization of conditionally IMECs
derived from the Immortomouse
In contrast with previous published experience using
this approach [23], we were able to readily generate pro-
pagatable mammary epithelial cell lines from Immorto-
mice for all our genotypes of interest. When initially put
into culture, the IMECs grew in epithelioid colonies,
and a significant fraction (~50%) of the cells underwent
cell death after 6 to 9 days in culture under permissive
growth conditions (33°C with IFNg), as evidenced by
slow culture expansion and floating debris. Thereafter,
the cultures stabilized and could be propagated with lit-
tle additional cell death. As seen in Figure 2a, tsTAg
protein was strongly induced by IFNg at 33°C, but not
at 37°C. Upon shifting of cells to 37°C, the tsTAg pro-
tein decayed to almost undetectable levels within 48
hours (data not shown). Unlike the conditionally IMEC
line that was established from a transgenic mouse
expressing the tsTAg from a b-lactoglobulin (BLG) pro-
moter (BLG-tsTAg) [23], our IMECs showed a cobble-
stone epithelial morphology at both permissive and
nonpermissive temperatures (Figure 2b), which was
maintained over all passages examined (up to passage
60). While cells proliferated continuously at 33°C, on
shifting to 37°C the growth rate of the culture slowed
significantly after day 3, with no further expansion of
the culture after day 6 (Figure 2c). This rapid loss of
proliferative capacity is also a feature of primary mam-
mary epithelial cultures. The following experiments
were therefore all performed within 5 days of shifting to
the nonpermissive conditions.
Consistent with their epithelial origin, the IMEC cul-
tures exhibited strong, culture-wide staining with a pan-
cytokeratin antibody, and were negative for the
mesenchymal marker vimentin (Figure 2d). The estab-
lished cultures are thus indeed epithelial, without fibro-
blast contamination. Using fluorescence-activated cell
sorting analysis, we found that almost all cells were
strongly positive for cytokeratin 14 - a basal epithelial
marker that is somewhat promiscuously expressed in
culture. The luminal cytokeratin 8 was weakly expressed
on ~50% of the culture (Figure 2e). It should be noted,
however, that mouse mammary epithelial cells have
been shown to be much less stable than their human or
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(a) Western blot of tsTAg expression in immortalized mammary epithelial cells (IMECs) grown in the presence or absence of added IFNg at
permissive (33°C) or nonpermissive (37°C) temperatures as indicated. b-actin used as a loading control. (b) Phase contrast images of wildtype
IMECs showing a cobblestone epithelial morphology under both permissive and nonpermissive conditions. White scale bar = 100 μm. (c)
Proliferation of IMECs under the permissive and nonpermissive growth conditions, showing rapid loss of proliferative capacity under
nonpermissive conditions. Results representative of two independent experiments. (d) Wildtype IMEC cultures were grown under nonpermissive
conditions and the expression of intermediate filament proteins was assessed by immunofluorescence using pancytokeratin or vimentin
antibodies. Swiss 3T3 fibroblasts were used as a positive control for vimentin expression. DAPI, 4’,6-diamidino-2-phenylindole. (e) Flow cytometric
analysis for expression of cytokeratins CK8 and CK14 in wildtype IMECs grown under nonpermissive conditions.
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specific cytoskeletal markers in vitro [24].
Following transplantation into the cleared mammary fat
pad of nude mice, we observed formation of a mammary
ductal tree in 1/20 implants using between 2.5 × 10
4 and 2
×1 0
6 unsorted IMECs/site (Figure 3a). While the effi-
ciency was low under the conditions used, this result sug-
gests that the IMECs retain some capacity to regenerate a
morphologically normal mammary epithelium, presum-
ably due to the presence of a small number of condition-
ally immortalized stem cells in the culture.
The conditionally IMEC line KIM-2 that was gener-
ated from the mid-pregnant gland of the BLG-tsTAg
transgenic mouse, and the spontaneously immortalized
HC11 line also derived from a mid-pregnant mouse,
both have the capacity to functionally differentiate in
response to lactogenic hormones in vitro [23,25]. Our
IMECs were derived from virgin mice and did not
undergo lactogenic differentiation (Figure 3b). Deriva-
tion of parallel lines from mid-pregnant animals, how-
ever, should permit this aspect of mammary biology to
be examined in vitro.
Primary human mammary epithelial cells are extre-
mely sensitive to growth inhibition by TGFb [26]. We
found that proliferation of primary mouse mammary
epithelial cells was also strongly inhibited by TGFb,a n d
that our IMECs showed an essentially identical growth
inhibitory response to TGFb as the primary mouse
mammary epithelial cells (Figure 3c). This was true for
two independent IMEC isolates, and the property was
stable for over 60 passages in culture. The IMECs there-
fore represent a viable and stable model in which to
examine TGFb responses.
Generation of IMECS of different Smad genotypes
To delineate the roles of Smad2 and Smad3 in the
mammary epithelium, we intercrossed the Immorto-
mouse with two different genetic models of Smad dele-
tion. To address requirements for Smad3, the germline
knockout Smad3DelEx8 mouse was used [16]. For
Smad2, we used a Smad2 conditional knockout mouse
in which exon2 is flanked with loxP sites [12]. We thus
generated IMECS of the following four genotypes: wild-
type, Smad3
-/-, Smad2
fl/fl, and Smad3
-/-;Smad2
fl/fl.
Prior to excision of the floxed alleles, Smad2
fl/fl IMECs
behaved identically to wildtype IMECs and were used
interchangeably in some experiments. To generate
Smad2 null IMECs, Smad2 was excised from IMEC cul-
tures by ex vivo incubation with adenovirus expressing
the Cre recombinase, and subsequent experiments were
carried out either with bulk culture or with clonal iso-
lates; similar results were obtained with both. Western
Figure 3 Functional characterization of immortalized mammary
epithelial cell cultures. (a) Whole mount of a reconstituted
mammary gland generated by transplantation of 2.5 × 10
4
immortalized mammary epithelial cells (IMECs) into a cleared
mammary fat pad. (b) PCR analysis of b-casein mRNA expression as
an indicator of lactogenic differentiation. IMECs growing in two-
dimensional culture under nonpermissive conditions were exposed
to lactogenic hormones for 3 days prior to isolation of mRNA for
analysis. RNA from HC11 cells treated in the same way and RNA
isolated from a mid-pregnant mammary gland were used as
positive controls. (c) Responsiveness to transforming growth factor
beta (TGFb)-mediated growth inhibition in IMECs and primary
mammary epithelial cells (MECs) was determined under
nonpermissive conditions by assessing incorporation of [
3H]
thymidine. Results are means of triplicate determinations. IMEC-A
and IMEC-B are independently generated IMEC cultures derived
from different mice, isolated several months apart. The responses of
early (P20) and late (P64) passage cultures of IMEC-A were
compared.
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floxed Smad2 allele was obtained by this approach (Fig-
ure 4a). The wildtype, Smad2 null and Smad3 null cells
were morphologically similar in culture, with the excep-
tion that colonies formed by Smad3 null cells generally
had tighter, more defined borders (Figure 4b). Cultures
in which either Smad2 or Smad3 were deleted showed
similar growth characteristics to wildtype cultures at the
permissive temperature (Figure 4c), while at 37°C
Smad2 null cells and Smad3 null cells proliferated
slightly faster than wildtype cells, but proliferation rates
greatly decreased in all genotypes within a few days (Fig-
ure 4d). Interestingly, although double-null IMECs
appeared viable following ex vivo deletion of Smad2 in
Smad3 null cells (data not shown), they could not be
further propagated at either permissive or nonpermissive
temperatures. This observation suggests that mammary
epithelial cells require some level of at least one of the
two Smads for continued proliferation. We were there-
fore unable to perform further studies on the Smad2/3
double-null cells.
We also assessed whether loss of one Smad had any
effect on TGFb signaling through the other Smad. Loss
of Smad3 had essentially no effect on TGFb signaling
through Smad2, as assessed by western blot analysis of
Smad2 phosphorylation, whereas loss of Smad2 caused a
slight reduction in the level of Smad3 phosphorylation
by TGFb (Figure 4e). Consistent with this observation of
slightly reduced TGFb signaling in the Smad2 null cells,
we observed a 50% reduction in TGFb receptor type II
mRNA in Smad2 null cells (Figure 4f).
Smad3, but not Smad2, is required for TGFb-induced
growth inhibition and apoptosis in the mammary
epithelium
TGFb has tumor-suppressive activity in many normal
epithelia, and the inhibition of proliferation and/or the
induction of apoptosis are likely to contribute to this
activity (reviewed in [27]). We therefore sought to deter-
mine whether these activities were dependent upon
Smad2, Smad3, or both in the mammary epithelium.
Incubation of wildtype IMECs with TGFb in the pre-
sence of insulin, to suppress apoptosis, resulted in
potent growth inhibition, with ~80% growth arrest at 1
to 5 ng/ml TGFb (Figure 5a). IMECs that lacked Smad2
were growth inhibited as efficiently as wildtype IMECs.
Loss of Smad3, however, greatly reduced the sensitivity
of the IMECS to TGFb-induced growth arrest. Our pre-
vious experiments with primary MECs had suggested
that Smad3 was not necessary for growth inhibition by
TGFb [28]. Only a single high concentration of TGFb
was tested in that study, however, and the growth inhi-
bition achieved by the TGFb was much less extensive,
so the dependence on Smad3 was not readily apparent.
We have subsequently found the growth inhibitory
effect of TGFb on MECs to be very dependent on cul-
ture conditions. In the more physiologically relevant
dose range under optimized culture conditions, our cur-
rent study shows that Smad3 is clearly necessary for a
significant growth inhibitory response to TGFb,w h i l e
Smad2 is dispensable.
Incubation of wildtype IMECs with TGFb in the
absence of added insulin resulted in a potent induction
of apoptosis (Figure 5b), consistent with the known role
of TGFb in driving apoptosis during involution [4]. We
have previously shown that Smad3 was required for this
response in vivo, but we did not address the role of
Smad2 [28]. Using the IMECs, we found that deletion of
Smad3 completely ablated the ability of TGFb to induce
apoptosis, even at the highest tested concentrations of
TGFb, whereas deletion of Smad2 reproducibly rendered
cells nearly twofold more sensitive to induction of apop-
tosis by TGFb, when compared with wildtype cells (Fig-
ure 5b). Smad2 expression is thus not required for
induction of apoptosis in the mammary epithelium, and
may actually oppose the apoptosis-inducing effects of
TGFb, whereas Smad3 is absolutely required for this
response.
Knockout of either Smad2 or Smad3 eliminates the
induction of cell migration and invasion by TGFb
As carcinoma cells develop resistance to the tumor sup-
pressive effects of TGFb in late-stage disease, tumor-
promoting biological responses such as the stimulation
of cell migration and invasion become more dominant
(reviewed in [1]). We found that wildtype IMECs were
capable of migrating in Transwell assays in response to
TGFb, exhibiting a 15-fold to 20-fold increase in migra-
tion over untreated cells (Figure 5c). The cells also
showed a low level of basal invasion through Matrigel
that could be induced nearly sixfold by treatment with
TGFb (Figure 5d). Cells that lacked either Smad2 or
Smad3, however, lost their ability to migrate or invade,
both basally and in response to TGFb.T h e r e f o r e ,a s
opposed to the growth inhibition and apoptotic
responses for which Smad3 alone was necessary and suf-
ficient, expression of both Smads appears to be required
for induction of the migratory and invasive responses by
TGFb.
Smad2 and Smad3 function interchangeably in the
invasion response
A dependence on both Smad2 and Smad3 could either
reflect an independent requirement for each Smad to be
present, or it might indicate that the two Smads are
interchangeable for eliciting the invasion response but
that a threshold level of R-Smad must be exceeded for
the response to occur. To differentiate these two
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Page 8 of 16Figure 4 Characterization of immortalized mammary epithelial cell cultures with different Smad genotypes. (a) Western blot analysis of
Smad2 and Smad3 expression in different immortalized mammary epithelial cell (IMEC) cultures. Smad2 was excised from IMECs that were
homozygous for the conditional allele of Smad2 (Smad2
fl/fl)b yex vivo exposure to adenovirus expressing Cre recombinase. Adenovirus
expressing LacZ was used as a control for nonspecific effects of viral transduction. Mouse embryo fibroblasts (MEFs) derived from germline
Smad2 knockout mice (S2KO) were used as a positive control for complete Smad2 deletion. b-actin used as a loading control. WT, wildtype. (b)
Morphology of Smad null cultures under nonpermissive conditions. White scale bar = 100 μm. (c) Long-term growth curves for the various IMEC
cultures grown under permissive conditions. Growth plotted as cumulative population doublings. Results are representative of two independent
experiments. (d) Short-term growth curves for the various IMEC cultures after shifting to nonpermissive conditions. Results are the mean ±
standard error of the mean for three independent experiments. (e) Western blot of Smad phosphorylation in response to transforming growth
factor beta (TGFb) (2 ng/ml for 30 minutes) in the IMECs of different genotypes. Note that the phospho-Smad3 antibody also recognizes
phospho-Smad1, phospho-Smad5 and phospho-Smad8, which comprise the upper of the two bands on the phospho-Smad3 blot. (f)
Quantitative RT-PCR assessment of TGFb receptor type II (TGFBR2) mRNA. Data are normalized to the wildtype genotype. *P < 0.05 for
expression difference between specified genotype and wildtype control (Student’s t test). AU, arbitrary units.
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Page 9 of 16Figure 5 Smad2 and Smad3 are differentially required for different TGFb-mediated biological responses. Immortalized mammary
epithelial cells (IMECs) of different Smad genotypes were shifted to nonpermissive temperatures and then assessed for their ability to respond to
varying concentrations of transforming growth factor beta (TGFb) in the following biological assays as described in Materials and methods: (a)
growth inhibition, (b) apoptosis, (c) migration, and (d) invasion. For the growth inhibition and assays, all data are normalized to the control
condition (no added TGFb) for the respective genotype group. For migration and invasion, data are normalized to the wildtype (WT) IMECs, no
added TGFb control condition. LacZ indicates Smad2
fl/fl cells that have been exposed to the LacZ control adenovirus and therefore have a
wildtype complement of Smad2 and Smad3. Data are the mean ± standard deviation of three determinations. All experiments were repeated at
least twice with essentially the same results. (a, b) *P < 0.05 for the difference between the indicated Smad genotype and wildtype control. (c, d)
*P < 0.05 for the difference between specified pairwise comparisons.
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Page 10 of 16possibilities, Smad2 or Smad3 were reintroduced into
IMECs of the various null genotypes by adenoviral
transduction. Ectopic expression of Smad2 in Smad2-
deleted cells or Smad3 in Smad3 null cells was sufficient
to rescue sensitivity to TGFb-induced invasion, giving
levels of induction that were comparable with those
seen in wildtype cells (Figure 6a). This add-back experi-
ment confirms that Smad-deficient cultures were unable
to invade because Smad2 and Smad3 are required for
this biological response, and not because of some Smad-
independent difference in the cell populations due to
adaptation to the loss of a Smad. Interestingly, when
Smad3 was introduced into Smad2 null IMECs, and
Smad2 into Smad3 null cells, the transduced cells
regained 60 to 70% of their invasive capacity - suggest-
ing that the two Smads are essentially interchangeable
for this biological response, and that a threshold level of
expression of either Smad must be exceeded for inva-
sion to occur (Figure 6b).
Smad dependency of the TGFb-induced epithelial-to-
mesenchymal transition and regulation of
metalloproteinases
TGFb is a strong inducer of EMT in many biological
systems, with a variable requirement for the R-Smads
depending on the cell type studied [29]. In general, how-
ever, TGFb-induced EMT appears dependent on Smad3,
a n dS m a d 2m a yp l a ya no p p o s i n gr o l eb ym a i n t a i n i n g
an epithelial morphology under basal conditions [12,30].
When we excised Smad2 ex vivo in our IMEC cultures,
av e r ys m a l lf r a c t i o no ft h ep o p u l a t i o nd i ds p o n t a -
neously acquire a spindled appearance (data not shown),
and the identity of this susceptible subpopulation will
require further study. Unlike the situation with hepato-
cytes [12], however, the bulk of the Smad2 null IMEC
population retained an epithelial morphology in the
basal state, although there was some evidence for mole-
cular changes consistent with a partial EMT (see below).
None of the IMEC lines we developed responded to
exogenously added TGFb with a classic morphological
EMT (data not shown). The widely-studied NMuMG
mouse mammary epithelial cell line seems to be unu-
sually sensitive to induction of EMT by TGFb [31], as
only a minority of cell lines from a large panel of nor-
mal and transformed breast epithelial cell lines showed
such a strong response in the 48-hour timeframe [32].
Despite the absence of a morphological EMT, however,
we saw molecular evidence suggesting that a partial
EMT does occur in response to TGFb in the wildtype
and Smad2 null IMECS, but not in the Smad3 null cells.
Furthermore, the Smad2 null IMECs showed some indi-
cation of early EMT-related changes in the bulk culture
in the untreated state. E-cadherin was localized primar-
ily at cell-cell junctions of untreated cultures of wildtype
and Smad3 null cells, although this feature was less
clear in the Smad2 null cells (Figure 7a). In response to
treatment with TGFb, E-cadherin was delocalized and
p a r t i a l l yl o s tf r o mw i l d t y p ea n dS m a d 2n u l lI M E C s ,b u t
not from Smad3 null IMECs. Similarly, phalloidin stain-
ing for F-actin showed a weakly positive cortical distri-
bution in untreated wildtype and Smad3 null cells,
which was not readily apparent in Smad2 null cells. Fol-
lowing treatment with TGFb, both wildtype and Smad2
null cells, but not Smad3 null cells, showed formation of
actin stress fibers. This partial induction by TGFb of
features of EMT in the wildtype and Smad2 null cells
was supported by the demonstration that TGFb could
induce expression of Snail, a transcriptional regulator of
EMT, in wildtype and Smad2 null cells, but not in
Smad3 null cells (Figure 7b). In contrast, expression of
Twist and Slug was relatively unaffected by TGFb in all
three cell types. Consistent with the induction of some
mesenchymal-like properties, TGFb also induced the
upregulation of fibronectin mRNA in wildtype and
Smad2 null IMECs, but not in Smad3 null IMECs (Fig-
ure 7c).
Therefore, as has been observed in other cell types
[12,33,34], the ability of TGFb to induce features of
EMT in IMECs is dependent on the presence of Smad3
but not of Smad2. Since the invasion and migration
responses to TGFb were lost in both Smad2 null and
Smad3 null IMECs while the EMT response was only
lost in the Smad3 null cells, we searched for a different
underlying mechanism to explain the Smad dependency
of the invasion response. Invasion is dependent on the
induction of metalloproteinases to degrade the extracel-
lular matrix, and TGFb is known to affect the expres-
sion and/or activity of several metalloproteinases [35].
Using gelatin zymography, we showed that the ability of
TGFb to induce MMP-9 is essentially lost in both
Smad2 null cells and Smad3 null cells (Figure 7d). The
ability of TGFb to increase MMP-9 activity thus shows
the same Smad dependency as the invasion response
program, and provides a plausible molecular underpin-
ning for the observed dependency pattern of the inva-
sion response.
Discussion
Understanding the detailed mechanisms by which var-
ious molecular mediators regulate mammary gland biol-
ogy is of strong interest in the study of both normal
physiology as well as disease states such as cancer. In
the present article, we have combined the power of
mouse genetics to totally ablate a gene of interest, with
a conditional immortalization approach that allows us to
overcome the challenge of generating sufficiently large
numbers of primary mouse mammary epithelial cells of
defined genotype for molecular and biochemical
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Page 11 of 16analysis. We have applied this approach to address the
roles of Smad2 and Smad3 in mediating TGFb
responses in the mammary epithelium. The results have
yielded interesting insights into TGFb signaling and the
approach is likely to be broadly applicable to other sig-
naling pathways.
The mammary epithelial cells that we generated by
this approach could be propagated essentially indefi-
nitely at the permissive temperature (at least 60 pas-
sages), but retained many of the properties of primary
cultures when shifted to the nonpermissive temperature,
including the epithelial morphology, expression of
epithelial cytokeratins, and responsiveness to the growth
inhibitory effects of TGFb. Importantly, only a single
female mouse of the desired genotype was required for
the isolation and propagation of large numbers of condi-
tionally immortalized cells for downstream molecular
and biological analyses. This feature of the approach is
particularly useful when multiple genes need to be
knocked out simultaneously, as with the Smad3
-/-;
Smad2
fl/fl;Im mice that had five independently segregat-
ing genetically modified alleles.
A related approach to the generation of conditionally
IMECs has previously been published, in which the
same tsTAg transgene was used, but expression was dri-
ven by the BLG milk protein promoter [23]. The MECs
generated from the BLG model appeared to show some
developmental plasticity and instability, irreversibly
developing a spindled non-epithelial morphology when
shifted to the permissive temperature, and acquiring the
ability to form colonies in soft agar, a characteristic of
transformed cells. In contrast, the various IMEC cul-
tures that we have generated from the Immortomouse
are phenotypically epithelial under permissive or non-
permissive conditions and have not transformed during
t h et i m ew eh a v em a i n t a i n e dt h e mi nc u l t u r e( u pt o6 0
passages). Furthermore, the BLG promoter is expressed
during mid-to-late pregnancy and lactation, restricting
generation of conditionally IMECs to those developmen-
tal stages. In contrast, the H-2Kb major histocompatibil-
ity promoter used in the Immortomouse should be
expressed at all developmental stages. In the present
study, we derived our mammary epithelial cells from vir-
gin mice, but there is no reason why the same approach
could not be used to generate conditionally immorta-
lized epithelial cells from pregnant, lactating, involuting
or postinvolution glands to address the molecular con-
text changes and biological features expressed at these
different stages. Indeed, since each mouse has multiple
mammary glands, it should be possible to derive cells
representing different stages of functional differentiation
Figure 6 Exogenous Smad2 or Smad3 expression restores
TGFb-mediated invasion in immortalized mammary epithelial
cells lacking Smad. (a) Adenoviral expression of Smad2 in Smad2
null cells, or of Smad3 in Smad3 null cells, restores sensitivity to
transforming growth factor beta (TGFb)-induced invasion. (b)
Adenoviral expression of Smad3 in Smad2 null cells, or of Smad2 in
Smad3 null cells, largely restores sensitivity to TGFb-induced
invasion. All values normalized to wildtype (WT) control values.
Results are the mean ± standard deviation of three determinations.
*P < 0.05 for the difference between specified pairwise
comparisons. Western blot analysis of Smad expression in
adenovirally transduced immortalized mammary epithelial cells
(IMECs) is shown for each experiment. b-actin used as a loading
control. NS, not significant.
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Page 12 of 16Figure 7 Smad dependency of induction of molecular markers of epithelial-to-mesenchymal transition and of MMP-9 by TGFb. (a)
Immunofluorescent staining for E-cadherin and F-actin following 48 hours with or without treatment with 2 ng/ml transforming growth factor
beta (TGFb). (b) Quantitative RT-PCR determination of mRNA levels for key transcriptional regulators of EMT under the same treatment
conditions as (a). All data are normalized to the no TGFb condition for each genotype. *P < 0.05 for the difference between the TGFb-treated
and control conditions. (c) Quantitative RT-PCR for fibronectin mRNA. Data normalized to the wildtype (WT) genotype, no TGFb treatment. *P <
0.05 for the difference between the TGFb-treated and control conditions. (d) Gelatin zymography of cell-conditioned medium following 48 hours
with or without treatment with 2 ng/ml TGFb. Medium indicates medium alone control; MMP-2 is present in the serum contained in the culture
medium.
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Page 13 of 16from the same mouse. We therefore feel that use of the
Immortomouse complements existing approaches and
offers some significant additional advantages.
To illustrate the utility of this approach, we generated
a novel panel of conditionally immortalized lines with
different Smad genotypes that we then used to assess
the relative dependency of different biological responses
to TGFb on the downstream mediators, Smad2 and
Smad3. We found distinct patterns of dependency on
the two Smads as summarized in Table 1.
For TGFb to induce growth inhibition, apoptosis or a
partial EMT in the mammary epithelial cells, we found
that Smad3 but not Smad2 was required. Indeed, Smad2
partially opposed the effect of TGFb in inducing apopto-
sis, and provided some protection against EMT-like
changes in the basal state. This pattern of Smad depen-
dency has also been observed by other researchers in
different cell types. Smad3 is the critical mediator of
growth inhibitory and proapoptotic responses to TGFb
in primary murine hepatocytes, a mouse mammary
epithelial cell line, and a human keratinocyte cell line
[12,36,37]. Similarly, Smad3 is essential for TGFb to
induce pathological EMT in the renal tubulointerstitial
epithelium and the lens epithelium of the eye [33,34].
The ability of Smad2 to oppose or reduce certain
Smad3-dependent responses has also been observed by
others, for the growth inhibitory effect of TGFb [15], for
the EMT response [12] and for some transcriptional
responses [15,12,38]. Opposing effects of Smad2 and
Smad3 on transcriptional regulation of the goosecoid
gene have been ascribed to competition between Smad3
and Smad4 for binding to the Smad binding element
adjacent to the FAST2/Smad2 binding site [38].
A completely different pattern of Smad dependency
was observed for TGFb-induced migration and invasion
responses in the mammary epithelial cells. In this pre-
sent article, we showed that knockout of either Smad2
or Smad3 eliminated these two biological responses,
initially suggesting to us that both Smads were required.
In add-back experiments, however, we found that over-
expression of Smad3 could substitute for loss of Smad2,
and vice versa, in restoring the invasion response. The
invasion response may therefore require a critical
threshold level of activated Smad that can be supplied
by either Smad2 or Smad3 when present in sufficient
quantity. A similar mechanism has also been implicated
in early mouse embryo development where one Smad
appears to be able to substitute for the other in rescuing
some of the developmental phenotypes [10]. We further
showed that the ability of TGFb to induce MMP-9
activity was also lost on ablation of either Smad2 or
Smad3, suggesting one possible molecular effector pro-
gram that might underlie the observed Smad depen-
dency of the invasion response.
The differential Smad requirement for the regulation
of different biological responses could be attributable to
the differences in the Smad interactomes. Both Smad2
and Smad3 have sizeable interactomes, consisting of
many DNA-binding proteins and transcriptional cofac-
tors [39,40]. The majority of these proteins can interact
with either Smad2 or Smad3, and the transcriptional
programs mediated by these common interactors may
underlie those biological responses that are regulated by
either/both Smads. There are a number of transcrip-
tional partners that only bind to Smad3, however, such
as the C/EBPs, several FoxO family members, ATF3,
and certain steroid hormone receptors [39]. This class
of interactors may be important for responses that are
specifically dependent on Smad3. The requirement of a
particular biological response for a given Smad is there-
fore likely to be highly dependent on the molecular con-
text provided by the spectrum of transcriptional
cofactors and modulators that are expressed in a given
cell. Genome-wide approaches to identify Smad target
genes, such as ChIP-chip and ChIP-seq, will provide
important insights into these questions [41,42].
It is tempting to extrapolate from our results on the
normal mammary epithelium to suggest that Smad2
might be a better molecular target than TGFb for breast
cancer therapy, since Smad2 appears only to be required
for TGFb responses that might promote tumorigenesis
(migration and invasion) and not for potentially tumor
suppressive responses (growth inhibition and apoptosis).
In the epidermis, however, Smad2 has been shown to
Table 1 Receptor-activated Smad dependency of different biological responses to TGFb in mammary epithelial cells
Biological response to TGFb Potential role in
tumorigenesis
Receptor-activated Smad requirement
Growth inhibition Tumor suppression Smad3
Apoptosis Tumor suppression Smad3; Smad2 opposes
Migration and invasion Pro-progression Smad2 or Smad3; a threshold level of receptor-activated Smad must be
exceeded
Epithelial-to-mesenchymal transition Pro-progression Smad3; Smad2 opposes basally
Induction of metalloproteinases
(MMP-9)
Pro-progression Smad2 or Smad3
Smad, Sma and MAD (mothers against decapentaplegic)-related protein; TGFb, transforming growth factor beta.
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Page 14 of 16have tumor suppressor activity [30]. Furthermore, in rat
prostatic epithelial cells, Smad2 was shown to be critical
for the proapoptotic effect of TGFb in a premalignant
basal cell line (NRP152), while Smad3 mediated the
apoptotic response in a malignant luminal carcinoma
cell line (NRP154) derived from the same rat prostate
[43]. Together, these data suggest that the requirement
for a specific Smad may vary with the nature of the tar-
get epithelium, the differentiation state of the cell, and/
or the stage of malignant progression. This issue needs
to be further addressed in the mammary epithelium.
Introducing oncogenic lesions by transgenic breeding
strategies or by ex vivo transduction of IMECs could
provide one approach to this question.
Conclusions
We have developed an experimental approach that
allows the generation and continued propagation of con-
ditionally immortalized mammary epithelial cells from
mice with defined genetic lesions. Using the TGFb path-
way as a model, we demonstrated the utility of this
strategy by elucidating the Smad dependency of a num-
ber of key biological responses to TGFb. This approach
represents a powerful tool for exploring cell biology,
and could be readily applied to other signaling pathways
and to different stages in mammary gland development
and/or malignant progression.
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